Drugs / Mevonlerbart
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02127801 | Oct 2014 → Dec 2015 | allergic disease | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 32 trials · 1 met primary | ||||||
| Phase 3 | NCT07675811 | Jul 2026 → Oct 2027 expected | conjunctivitis | Regeneron Pharmaceuticals | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06602726 | Nov 2024 → May 2025 | conjunctivitis | Regeneron Pharmaceuticals | Completed | Met primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-09-08 | Regeneron Pharmaceuticals | Results Regeneron Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-in-Class Antibody-Blockers of Cat and Birch Allergies regeneron.com ↗
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced results evaluating its first-in-class investigational allergen-blocking antibodies in allergen-challenge Phase 3 trials in adults with moderate-to-severe cat or birch allergies. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-09-08 | Regeneron Pharmaceuticals | Regeneron Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-in-Class Antibody-Blockers of Cat and Birch Allergies regeneron.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Mevonlerbart | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07675811 ↗ |
| Known as | REGN1909 | “Ex vivo assays demonstrated that REGN1908 and REGN1909 combined were more potent than each alone for inhibiting FcεRI- and FcεRII (CD23)-mediated allergic responses and...” PMID 33651675 ↗ Jul 2021 |
| Action | Inhibit | “Ex vivo assays demonstrated that REGN1908 and REGN1909 combined were more potent than each alone for inhibiting FcεRI- and FcεRII (CD23)-mediated allergic responses and...” PMID 33651675 ↗ Jul 2021 |
| Modality | Monoclonal antibody | “anti-Fel d 1 monoclonal antibodies (REGN1908-1909)” PMID 33651675 ↗ Jul 2021 |